Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...
The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...
Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...
Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...
Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...
The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...
We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...
Austedo remains a standout performer, with analysts projecting continued strong sales growth. UZEDY, another important product in Teva's lineup, is also expected to contribute significantly to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results